Loading…
Based on limited metadata, reBom Co., Ltd. received an FDA Warning Letter on June 26, 2024, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the full scope and details of the violations cited, the complete Warning Letter would need to be reviewed.